Stem cell therapy is no longer just a promise on the horizon. In 2025 and 2026, it’s a $28 billion field with approved treatments, landmark trial results, and patients whose lives have genuinely changed. Here’s the honest clinical scorecard.
Neurological diseases: the most dramatic results
Of all the disease areas where stem cell therapy is showing real clinical promise, neurology has produced some of the most striking results in 2025 and 2026. For decades, neurological damage — from Parkinson’s disease to spinal cord injury to ALS — was considered essentially permanent, because neurons in the central nervous system don’t regenerate. Stem cell therapy is beginning to challenge that assumption directly.
In one of the most-cited cases of 2025, a Phase I clinical trial run by Neurona Therapeutics treated 15 patients with severe, treatment-resistant epilepsy by transplanting lab-grown inhibitory neurons directly into their brains. These neurons were engineered from stem cells to suppress the electrical misfires that cause seizures. The results shocked the medical team: multiple participants showed dramatic reductions in seizure frequency — in conditions where all other treatments had failed.
🧠 Parkinson’s disease update: A Phase II/III trial published in Nature Medicine (2025) demonstrated safety and statistically significant improvement in motor scores at 12-month follow-up in Parkinson’s patients treated with iPSC-derived dopaminergic neurons — the specific cell type destroyed by Parkinson’s disease. This is one of the most advanced iPSC cell therapy programs in neurology.
ALS: slowing a disease that never slows down
ALS — amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease — is one of the most devastating neurological conditions known, progressively destroying the motor neurons that control movement, swallowing, and breathing. It has no cure, and until recently, no treatment produced meaningful slowing of its progression.
A Phase II randomized controlled trial, published in The Lancet and highlighted in the 2026 stem cell therapy review by Top Doctor Magazine, demonstrated statistically significant slowing of motor function decline in ALS patients treated with intrathecal neural stem cell injections — meaning the stem cells were delivered directly into the cerebrospinal fluid surrounding the spinal cord. While this is not a cure, statistically significant slowing of ALS progression is a major milestone in a disease that has resisted treatment for generations.
Epilepsy: transplanted neurons that actually work
The Neurona Therapeutics epilepsy trial represents a paradigm shift beyond just the results. The concept that you can take stem cells, differentiate them into a specific neuron type needed to correct a circuit imbalance in a patient’s brain, and transplant them effectively — with neurons that survive, integrate, and function — was not considered clinically viable even five years ago. The 2025 results suggest it is not only viable but may be one of the most powerful tools available for neurological conditions driven by specific circuit dysfunctions.
Autoimmune diseases: 449 trials and growing
A comprehensive analysis of global clinical trial data published in PMC (2025) identified 449 clinical trials on stem cell therapy for autoimmune rheumatic diseases alone — with 75.8% using mesenchymal stem cells (MSCs). Osteoarthritis accounted for 46.7% of targeted conditions, followed by rheumatoid arthritis at 12.6%.
MSCs are particularly attractive for autoimmune conditions because of their immunomodulatory properties — they can suppress overactive immune responses and reduce inflammation without the systemic side effects of conventional immunosuppressant drugs. A 2025 Chinese study identified thiamine monophosphate (TMP) as a predictive biomarker for MSC response in systemic lupus erythematosus (SLE), with patients identified as likely responders showing remission rate improvements of 78%.
📊 Success rates by condition (2026 data): Blood disorders and bone marrow transplants: 60–92% success. Epilepsy (Neurona Phase I): dramatic seizure reduction in multiple participants. Parkinson’s (Nature Medicine iPSC trial): improved motor scores at 12 months. ALS (The Lancet Phase II): statistically significant slowing of decline. Corneal stem cells (Osaka University): improvement in 3 of 4 patients at 2-year follow-up.
Where it hasn’t worked — and why honesty matters
Not every stem cell approach has delivered on its early promise. A 2025 meta-analysis published in PMC found that MSC therapy for heart failure produced no significant improvement in left ventricular ejection fraction across 12 trials — a sobering result for one of the most-tested applications of stem cell therapy. The likely reason: wrong cell type, insufficient engraftment, or the wrong delivery approach for the specific biological problem.
This is actually important scientific progress. Understanding why stem cell therapies fail in specific contexts is as valuable as knowing when they succeed. It drives the field toward more targeted approaches: better cell types, better delivery mechanisms, better patient selection, and better understanding of which biological problems stem cells can realistically address.